Phase I Clinical Trial of Costimulated, IL-4 Polarized Donor CD4+ T Cells as Augmentation of Allogeneic Hematopoietic Cell Transplantation  by Fowler, Daniel H. et al.
P
D
H
I
l
h
c
Biology of Blood and Marrow Transplantation 12:1150-1160 (2006)
 2006 American Society for Blood and Marrow Transplantation
1083-8791/06/1211-0001$32.00/0
doi:10.1016/j.bbmt.2006.06.015
1hase I Clinical Trial of Costimulated, IL-4 Polarized
onor CD4 T Cells as Augmentation of Allogeneic
ematopoietic Cell Transplantation
Daniel H. Fowler,1 Jeanne Odom,1 Seth M. Steinberg,1 Catherine K. Chow,2 Jason Foley,1
Yelena Kogan,1 Jeannie Hou,1 Juan Gea-Banacloche,1 Claude Sportes,1 Steven Pavletic,1 Susan Leitman,3
Elizabeth J. Read,3 Charles Carter,3 Arne Kolstad,4 Rebecca Fox,5 Gregory L. Beatty,5
Robert H. Vonderheide,5 Bruce L. Levine,5 Carl H. June,5 Ronald E. Gress,1 Michael R. Bishop1
1Center for Cancer Research, 2Department of Radiology, and 3Clinical Center, Department of Transfusion
Medicine, National Institutes of Health, Bethesda, Maryland; 4Norwegian Radium Hospital, Oslo, Norway;
5Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania
Correspondence and reprint requests: Daniel H. Fowler, MD, NIH, 9000 Rockville Pike, Building 10, 3-East Labs,
3-3330; Bethesda, MD 20892 (e-mail: dhfowler@helix.nih.gov).
Received May 24, 2006; accepted June 28, 2006
Parts of this report was presented at the 2004 Meeting of the American Society of Hematology; Biology and Blood
Marrow Transplantation 2003;9:162-169; and Clinical Gastroenterology and Hepatology 2004;2:237-245.
ABSTRACT
The primary objective of this clinical trial was to evaluate the safety, feasibility, and biologic effects of
administering costimulated, interleukin (IL)-4 polarized donor CD4 T cells in the setting of HLA-matched
sibling, T cell-replete allogeneic hematopoietic cell transplantation (HCT). Forty-seven subjects with hema-
tologic malignancy received granulocyte colony-stimulating factor-mobilized allogeneic hematopoietic cell
transplants and cyclosporine graft-versus-host disease (GVHD) prophylaxis after reduced intensity condition-
ing. Initial subjects received no additional cells (n  19); subsequent subjects received additional donor CD4
T cells generated ex vivo by CD3/CD28 costimulation in medium containing IL-4 and IL-2 (administered day
1 after HCT at 5, 25, or 125  106 cells/kg). Studies after HCT included measurement of monocyte IL-1 and
tumor necrosis factor , detection of T cells with antitumor specificity, and characterization of T cell cytokine
phenotype. The culture method generated donor CD4 T cells that secreted increased T helper 2 (Th2)
cytokines and decreased T helper 1 (Th1) cytokines. Such Th2-like cells were administered without infusional
or dose-limiting toxicity. The Th2 cohort had accelerated lymphocyte reconstitution; both cohorts had rapid
hematopoietic recovery and alloengraftment. Acute GVHD and overall survival were similar in the Th2 and
non-Th2 cohorts. Th2 cell recipients tended to have increased monocyte IL-1 and had increased tumor
necrosis factor  secretion. CD8 T cells with antitumor specificity were observed in Th2 and non-Th2 cohorts.
Post-transplantation T cells from Th2 cell recipients secreted IL-4 and IL-10 (Th2 cytokines) and IL-2 and
interferon  (Th1 cytokines). Allograft augmentation with costimulated, IL-4-polarized donor CD4 T cells
resulted in activated Th1, Th2, and inflammatory cytokine pathways without an apparent increase in GVHD.
© 2006 American Society for Blood and Marrow Transplantation
KEY WORDS
Graft versus host disease ● Th2 cells ● Tetramers ● Cytokines
t
G
g
s
tNTRODUCTION
Allogeneic T lymphocytes mediate graft-versus-
eukemia (GVL) effects [1] and initiate graft-versus-
ost disease (GVHD), which remains the primary
omplication of allogeneic hematopoietic cell transplan- a
150ation (HCT) [2]. Immunosuppressive agents used for
VHD prophylaxis generally limit the success of allo-
eneic HCT to patients with indolent or chemotherapy-
ensitive malignancy [3-5]. Use of allogeneic HCT is
hus at an immunologic impasse because needs exist to
ugment antitumor effects and decrease GVHD.
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Th2 Cell Allograft Augmentation 1151GVHD pathogenesis involves donor interleukin
IL)-2 and interferon  (IFN-) secreting T helper 1
Th1) cells that promote monocyte IL-1 and tumor
ecrosis factor  (TNF-) secretion [6]. Murine T
elper 2 (Th2) cells, which secrete IL-4, IL-5, IL-10,
nd IL-13, can decrease GVHD [7,8]. In humans,
h1/Th2 balance may modulate GVHD, because do-
or IL-2 and IL-4 secretion was associated with in-
reased and decreased GVHD, respectively [9,10]. As
uch, Th2 cell graft augmentation represents a new
pproach to balance GVHD and GVL effects.
To generate Th2 cells, we modiﬁed an investiga-
ional method of T cell costimulation with anti-CD3/
D28-coated magnetic beads that yields CD4 cells
xpressing a polyclonal T cell receptor (TCR) reper-
oire [11]. This method has potential utility in alloge-
eic hematopoietic stem cell transplantation (HSCT)
ecause antigens accounting for GVHD and GVL
ffects are incompletely characterized. Anti-CD3/
D28-stimulated T cells, which secrete primarily
h1 cytokines [12], have been evaluated for therapy
f human immunodeﬁciency viral disease [13], lym-
homa [14], myeloma [15], leukemia [16], and as do-
or lymphocyte infusions [17]. In this phase I study,
e generated donor Th2 cells through costimulation
nd expansion in Th2-promoting cytokines (IL-4 and
L-2) [18] and evaluated their safety, feasibility, and
iologic effects when administered with T cell-replete
igure 1. Phase I clinical trial design. A, Donor apheresis. Steady-st
roduct; subsequently, granulocyte colony-stimulating factor (G-CS
roducts were cryopreserved. B, Treatment timeline. Subjects unde
onsisted of ﬂudarabine (30 mg/m2 per day) and cyclophosphamide
onsisted of cyclosporine A (CSA) that was initiated on day 1. Th
ay 1. C, To establish clinical results using a new immunoablativ
ithout Th2 cell infusion. Subjects were then sequentially enrolled
level 2; n  6), and 125  106 cells/kg (level 3; n  6). The proto
valuate in a preliminary manner whether Th2 cells might decreasllogeneic HCT. tETHODS
tudy Design, Accrual
A phase I, 4-arm, sequential study was designed
Figure 1). Initial subjects (n  19) underwent trans-
lantation without Th2 cells, as previously detailed
19]. Accrual to Th2 treatment arms occurred in a
ose-escalation manner at 5, 25, and 125  106 Th2
ells/kg. The numbers of subjects to be treated were 3
dose level 1), 3 (dose level 2), and 6 (dose level 3).
ne dose level 2 subject developed toxicity potentially
ttributable to Th2 cells (disseminated intravascular
oagulopathy); as per protocol design, 3 additional
ose level 2 subjects were accrued. Four of 6 subjects
eceiving dose level 2 did not develop acute GVHD.
ollowing protocol amendment, up to 18 additional
ubjects (maximum total of 24 subjects) were poten-
ially to have been treated at level 2 to have adequate
ower to determine in a preliminary manner whether
h2 cells decrease GVHD relative to non-Th2 recip-
ents. After accrual of 13 additional subjects, it was
etermined that acute GVHD was not decreased; be-
ause the study safety endpoint had been met, further
ccrual was stopped.
rotocol Implementation
The National Cancer Institute (NCI) and Univer-
ity of Pennsylvania institutional review boards and
he Food and Drug Administration approved the pro-
eresis was initially performed for ex vivo generation of the Th2 cell
apy was started for mobilization of the HCT cell product. Both cell
duction chemotherapy followed by preparative chemotherapy that
mg/m2 per day) on days 6, 5, 4, and 3. GVHD prophylaxis
cell product was infused on day 0; Th2 cell infusion occurred on
rative regimen, initial subjects (n  19) received allogeneic HCT
eive Th2 cells 5  106 cells/kg (level 1; n  3), 25  106 cells/kg
s then amended to allow further subject accrual to dose level 2 to
GVHD relative to the initial subjects not receiving Th2 cells.ate aph
F) ther
rwent in
(1200
e HCT
e prepa
to rec
col waocol. All subjects provided informed consent. Eligi-
b
p
c
f
a
n
l
w
t
a
c
s
E
5
v
m
p
p
c
c
t
t
w
e
f
d
D
p
c
b
w
m
I
c
m
w
G
a
g
(
r
K
I
u
M
t
s
3
C
c
w
b
p
A
C
a
E
t
o
h
t
h
t
i
s
M
w
p
u
i
t
C
i
w
D
m
(
m
t
w
r
s
w
R
P
t
u
t
I
i
c
s
s
(
T
t
b
l
C
a
D. H. Fowler et al.1152ility required a diagnosis of non-Hodgkin lym-
homa, Hodgkin disease, multiple myeloma, or
hronic lymphocytic leukemia that was primary re-
ractory or relapsed after second-line therapy or
utologous HCT. Subjects with chronic myeloge-
ous leukemia, myelodysplastic syndrome, and acute
ymphocytic or myelogenous leukemia in remission
ere also eligible. Additional criteria included age (16
o 75 years), Karnofsky performance status (70%),
nd adequate organ function. All patients had an ac-
eptable 6/6 (n  46) or 5/6 (n  1) HLA-matched
ibling donor.
Induction chemotherapy consisted of 1-3 cycles of
POCH-F (72-hour continuous infusion of etoposide
0 mg/m2 per day, doxorubicin 10 mg/m2 per day, and
incristine 0.5 mg/m2 per day; bolus cyclophospha-
ide 600 mg/m2 on day 4 and ﬂudarabine 25 mg/m2
er day on days 1-3; and oral prednisone 60 mg/m2
er day on days 1-4)] [19]. Transplant conditioning
onsisted of ﬂudarabine (30 mg/m2 per day  4) and
yclophosphamide (1200 mg/m2 per day  4). Hema-
opoietic progenitor cells were mobilized with ﬁlgras-
im (10 g/kg per day) and cryopreserved; ﬁlgrastim
as administered after HCT until neutrophil recov-
ry. Subjects received cyclosporine, which was tapered
rom day 100 to day 180 (or earlier for progressive
isease).
onor CD4 T Cell Polarization
Donors underwent steady-state apheresis, lym-
hocytes were enriched by elutriation [20], and red
ells were ACK lysed (Quality Biological, Gaithers-
urg, Md). B cells and CD8 T cells were depleted
ith anti-CD20 and anti-CD8 antibodies, sheep anti-
ouse beads, and a MaxSEP device (Baxter, Deerﬁeld,
ll). The suspension enriched for CD4 T cells was
ryopreserved, thawed, and stimulated with tosylate
agnetic beads (Dynal, Oslo, Norway) conjugated
ith anti-CD3 (OKT3; Ortho, Raritan, NJ) and
ood Manufacturing Practice-grade anti-CD28 9.3
ntibodies (3:1 bead:cell ratio). Culture occurred in
as-permeable bags (Baxter) using X-Vivo 20 media
BioWhittaker; Walkersville, Md), 5% donor plasma,
ecombinant human IL-4 (1000 IU/mL; Schering,
enilworth, NJ), and recombinant human IL-2 (20
U/mL; Chiron, Emeryville, Calif). Median cell vol-
me (MCV; femtoliters) was monitored (Coulter
ultisizer; Beckman Coulter, Fullerton, Calif) to de-
ermine the timing of restimulation, as previously de-
cribed [11]: when MCV decreased to 	500 ﬂ (range,
50-650 ﬂ), CD4 cells were restimulated with CD3/
D28 beads and propagated until MCV again de-
reased to 	500 ﬂ. Median CD4 expansion interval
as 18 days (range, 14-25 days). After expansion,
eads were removed, and cells were washed and cryo-
reserved for administration on day 1 after HSCT. sll infused T cell products met release criteria for
D4 T cell purity, viability, pyrogenicity, sterility,
nd absence of bead contamination.
nzyme-Linked Immunosorbent Assay
CD4 T cells were co-stimulated in the Th2 cul-
ure condition and received secondary co-stimulation
n day 12 of culture. On day 20 of culture, cells were
arvested, adjusted to 0.5  106 cells/ml, and received
ertiary re-stimulation with CD3/CD28 beads for 24
ours. Resultant supernatants were evaluated for cy-
okine content by triplicate testing using enzyme-linked
mmunosorbent assay (IL-4, IL-5, IL-10, IFN-: Bio-
ource, Camarillo, Calif; IL-2, IL-13: R&D Systems,
inneapolis, Minn). Linear ranges of cytokine assays
ere 16-4000 pg/mL for the IL-13 assay and 8-2000
g/mL for the other assays; samples were evaluated
ndiluted and at a 1:10 dilution to ensure that exper-
mental values were obtained from the linear aspect of
he standard curve.
linical Endpoints
Organ toxicity was scored by NCI Common Tox-
city Criteria (version 2.0). Acute and chronic GVHD
ere graded prospectively by standard criteria [21,22].
isease response was determined from computed to-
ographic measurements made by a radiologist
CKC) not involved in patient care and from bone
arrow examinations. Lymphoma response was de-
ermined by standard criteria [23]. Chimerism analysis
as by variable N-terminal repeat polymerase chain
eaction assay (Blood Center of SoutheasternWiscon-
in, Milwaukee, Wis); myeloid or T cell enrichment
as by magnetic beads (Miltenyi, Auburn, Calif) or
osetteSep (StemCell Technologies, Vancouver, BC).
ost-transplantation Absolute Lymphocyte Counts
Complete blood counts and lymphocyte differen-
ials were performed by the NIH Clinical Laboratory
sing a Cell-Dyn 4000 instrument (Abbott Diagnos-
ics, Abbott Park, Ill).
ntracellular Flow Cytometry
As previously detailed [24], mononuclear cells were
solated at 2, 4, and 6 weeks after transplantation and
ultured for 20-24 hours in medium containing monen-
in A (Golgi Stop; PharMingen, San Diego, CA). Re-
ultant cells were stained with anti-CD14 phycoerythrin
PharMingen), permeabilized, and stained with IL-1,
NF-, or isotype control antibodies (ﬂuorescein iso-
hiocyanate conjugated; PharMingen). Cells were gated
y forward and side scatters, which resulted in a popu-
ation that was 95% enriched for CD14 cells.
D14IL-1 or CD14TNF events were scored rel-
tive to isotype controls and the percentage of cytokine-
ecreting monocytes was calculated by the following for-
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Th2 Cell Allograft Augmentation 1153ula: [(CD14cytokine cells) 
 (CD14cytokine
ells  CD14cytokine cells)]. The number of evalu-
ble samples varied between time points because of fail-
re of sample to reach the research laboratory or insuf-
cient cell number to perform the assay.
etramer Analysis
Eight subjects who received HCT with Th2
ells (n  4) or without Th2 cells (n  4) were
LA-A2 and had sufﬁcient numbers of viable
ost-transplantation CD8 T cells available for tet-
amer analysis. Soluble HLA-A2 tetramers were
repared with indicated peptide epitopes and 2-
icroglobulin [25], conjugated to ﬂuorochrome,
nd validated using peptide-speciﬁc cytotoxic T
ymphocytes [26]. Control tetramers were speciﬁc
or immunodominant epitopes L11 from HTLV-1
TAX), G58 from inﬂuenza matrix protein, and
495 from cytomegalovirus pp65. Tetramers were
enerated that identify CD8 T cells speciﬁc for
ifferentiation antigens overexpressed in hemato-
ogic malignancy: survivin inhibitor of apoptosis
SURVIVIN) [27], preferentially expressed antigen
f melanoma (PRAME) [28], and Wilms tumor
ene 1 (WT1) [29]. Sur1M2 tetramer was used for
URVIVIN, and 4 unique tetramers were evaluated
or PRAME (PRA100, PRA142, PRA300, PRA425)
nd WT1 (WT10, WT1126, WT187, WT235).
ryopreserved peripheral blood mononuclear cells
rom day 60 or 90 after transplantation were
hawed and incubated with tetramers and with anti-
D8 ﬂuorescein isothiocyanate, and ﬂow cytometry
as performed as previously described [30].
ytokine Capture Flow Cytometry
Blood mononuclear cells were isolated by density
radient on days 6 and 7 after HCT from Th2 recip-
ents; this assay was developed during enrollment of
he non-Th2 cohort, and as such, results from this
ohort are not available. Day 6 samples were stimu-
ated with CD3/CD28 beads for 16-24 hours; day 7
amples were evaluated without stimulation. Cells
ere labeled with a bispeciﬁc antibody (IL-2, IFN-,
L-4, IL-10 catch antibodies combined with an anti-
D45 antibody; Miltenyi Biotec, Bergisch Glad-
ach, Germany) and stained with cytokine-speciﬁc
etection antibody and surface antibody; for each
ytokine evaluated, this staining represented a mix-
ure of mouse immunoglobulin G1 and G2a iso-
ypes, which were used as isotype controls to deﬁne
uadrants. In each case, results of the nonstimulated
cells using the anticytokine reagents were iden-
ical to those obtained with the costimulated T cells
sing the isotype controls; as such, results from the
onstimulated T cells served as a cellular control to
urther deﬁne ﬂow cytometric quadrants. Cytokine- mositive events of costimulated T cells were identi-
ed relative to results using isotype control antibod-
es and relative to results using the anticytokine
ntibodies on nonstimulated T cells; 2000 to 10 000
vents were acquired (FACScalibur instrument,
ellQuest software; Becton Dickinson). Some Th2
ell recipients were not evaluable for the assay due
o insufﬁcient cell number.
tatistical Analysis
Differences between cytokine values before and
fter culture were determined using the Wilcoxon
igned rank test applied to the percentage change
rom baseline to normalize for wide-ranging pretreat-
ent levels. Comparisons between cytokine levels in
h2 subjects and controls were made using the Wil-
oxon rank-sum test. Duration of survival was com-
uted from date of transplantation until date of death
r last known date when the subject was alive, with the
robability of survival computed by the Kaplan-Meier
ethod; statistical signiﬁcance of the difference be-
ween curves was determined by log-rank test. All P
alues are 2-tailed.
ESULTS
ytokine Polarization
Relative to freshly activated donor CD4 cells, ex-
anded donor CD4T cells had loss of IL-2 secretion
Figure 2; mean  SEM, 10 859  2622 versus 10
g/mL; P .0001), modestly decreased IFN- (2262
72 versus 949 257 pg/mL; P .12), increased IL-5
173  36 versus 1379  327 pg/mL; P  .0001),
ncreased IL-13 (138  28 versus 1727  623 pg/mL;
 .0001), and increased IL-4 (71  23 versus 187 
8 pg/mL; P  .017); secretion of IL-10 was abro-
ated after expansion (424  123 versus 16 pg/mL;
 .002). Because the Th2 shift was incomplete, T
ells generated by this method may be referred to as
h2-like cells. Feasibility of the method was 100%,
ecause expansion yielded sufﬁcient cells for each sub-
ect. CD4 T cells expanded 1746-fold (median;
ange, 301-16 118). The product contained primarily
D4 T cells (median, 99%), with nominal CD8 T
ell contamination (median, 0.2%).
ubject Characteristics
Th2 and non-Th2 cell cohorts had similar charac-
eristics (Table 1). The Th2 cohort was biased toward
alignancies considered to be at high risk for relapse
fter transplantation, as has been recently deﬁned [31];
e, Th2 subjects had high-risk malignancy in 16 of 28
ases (57%), whereas 6 of 19 non-Th2 subjects (32%)
ad high-risk malignancy (P2  .14, two-tailed Fisher
xact test). At study entry, 43 of 47 subjects (91%) had
easurable disease. EPOCH-F chemotherapy yielded
n
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D. H. Fowler et al.1154o complete responses (CRs) and a minority of partial
esponses.
raft Composition, Hematopoietic Recovery,
nd Alloengraftment
The doses of administered CD34 cells and
D3 T cells were similar between cohorts (Table 2).
igure 2. Cytokine phenotype of ex vivo expanded donor T cells. C
or cytokine phenotype before (Pre-Culture) and after (Post-Cultu
nd IL-2. Cell-free culture supernatants were generated by adjustin
or 24 hours; cytokine content was determined by enzyme-linked
*Statistically signiﬁcant difference between samples before and aft
able 1. Cohort Characteristics
ge (y), median (range)
ale/female
rior therapies, median (range)
rior autologous transplantations
easurable disease (study entry)
igh-risk malignancy*
Non-Hodgkin lymphoma, diffuse large cell
Multiple myeloma, refractory
Hodgkin lymphoma
Chronic myelogenous leukemia, accelerated phase
Chronic lymphocytic leukemia, transformed
ow-risk malignancy*
Non-Hodgkin lymphoma, follicular
Multiple myeloma, sensitive
Mantle cell lymphoma
Chronic lymphocytic leukemia
Myelodysplastic syndrome
Acute lymphocytic leukemia
Chronic myelogenous leukemia, chronic phase
esponse to EPOCH-F† chemotherapy, n evaluable
Complete response
Partial response
Stable disease
Progressive disease
High-risk and low-risk malignancies were deﬁned according to cr
Seventy-two-hour continuous infusion of etoposide (50 mg/m2 per dacyclophosphamide (600 mg/m2 on day 4) and ﬂudarabine (25 mg/m2 perecause of high T cell numbers present in the mobi-
ized allografts, Th2 cell administration modestly in-
reased total T cell dose; at dose level 3, the ratio of
h2 cells to mobilized T cells was approximately 1:3.
lloengraftment was rapid, because transplantation
ith or without Th2 cells yielded median donor chi-
erism 97% at day 14 after HCT.
cells isolated from initial protocol donors (n  15) were evaluated
3, CD28 costimulation and expansion in medium containing IL-4
cells to 0.5  106 cells/mL and stimulated with CD3/CD28 beads
osorbent assay through triplicate testing of culture supernatants.
re (P  .05).
on-Th2 Cohort (n  19) Th2 Cohort (n  28)
44 (19-67) 48.5 (25-69)
11/8 18/10
3 (0-6) 3 (1-6)
5 (26%) 6 (21%)
17 (89%) 26 (93%)
6 (32%) 16 (57%)
5 7
1 2
3
2
2
13 (68%) 12 (43%)
4 7
3
3 1
2 1
2
1
1
17 26
0 (0%) 0 (0%)
6 (35%) 11 (42%)
8 (47%) 8 (31%)
3 (18%) 7 (27%)
stablished by Bethge et al [31].
rubicin (10 mg/m2 per day), and vincristine (0.5 mg/m2 per day); bolusD4 T
re) CD
g CD4
immunN
iteria e
y), doxoday, days 1-3); and oral prednisone (60 mg/m2 per day, days 1-4).
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Th2 Cell Allograft Augmentation 1155linical Results
No infusional toxicities resulted from Th2 cell
nfusion (Table 3). Engraftment syndrome [32] oc-
urred in 42% of non-Th2 and 50% of Th2 recipi-
nts. Signiﬁcant organ toxicity (Common Toxicity
riteria grade 3) was relatively similar in non-Th2
nd Th2 cohorts. Seven of 10 cardiac events in Th2
ubjects were due to cyclosporine-induced hyperten-
ion, with 1 case each of arrhythmia, transient heart
able 2. Graft Composition, Engraftment, and Chimerism
raft composition, median (range)
CD34 dose (106/kg)
Mobilized CD3 dose (108/kg)
Mobilized CD3 dose plus Th2 dose (108/kg)
ematopoietic recovery, median (range)
Neutrophil recovery, ANC >500 per day
Platelet recovery, >20 000/L per day
lloengraftment* (% donor elements at day 14 after HCT), medi
Total mononuclear cells
Purified T cells
Purified myeloid cells
NC indicates absolute neutrophil count; HCT, hematopoietic ce
Percent donor elements determined by variable N-terminal repea
able 3. Clinical Results
Non-Th2 Cohort
(n  19)
Th2 Cohort
(n  28)
oxicity
Infusional toxicity 0 (0%) 0 (0%)
Engraftment syndrome 8 (42%) 14 (50%)
Renal 0 (0%) 2 (7%)
Neurologic 1 (5%) 2 (7%)
Pulmonary 7 (37%) 12 (43%)
Gastrointestinal 4 (21%) 5 (19%)
Cardiac 1 (11%) 10 (36%)
Coagulopathy 1 (11%) 2 (7%)
nfection
CMV reactivation 8/10 (80%) 13/19 (68%)
Bacterial 11 (58%) 14 (50%)
Fungal 5 (26%) 4 (14%)
Clostridium difficile 0 (0%) 9 (32%)
Herpes simplex or zoster 11 (58%) 14 (50%)
cute GVHD
Grade 0-I 7 (37%) 10 (36%)
Grade II 6 (32%) 8 (29%)
Grade III-IV 6 (32%) 10 (35%)
Skin 13 (68%) 9 (32%)
Liver 0 (0%) 4 (14%)
Gut 11 (58%) 13 (46%)
hronic GVHD
Total 10/13 (77%) 14/20 (80%)
Extensive 8/13 (62%) 11/20 (65%)
Limited 2/13 (15%) 3/20 (15%)
omplete remission rate
Day 28 after HCT 5/17 (29%) 9/25 (28%)
Day 100 after HCT 10/17 (59%) 14/22 (64%)
MV indicates cytomegalovirus; GVHD, graft-versus-host disease;
HHCT, hematopoietic cell transplantation.ailure, and myocardial infarction. Pulmonary compli-
ations were related to hypoxia during engraftment
yndrome. Infectious complications were similar ex-
ept for increased Clostridium difﬁcile infection in Th2
ecipients. Th2 and non-Th2 recipients had similar
ates of grade II (29% versus 32%) and grade III-IV
35% versus 32%) GVHD, a similar pattern of
VHD (skin and gut predominance), and similar
hronic GVHD.
The CR rates at days 28 and 100 after trans-
lantation were 29% and 59% in non-Th2 recipients
nd 28% and 64% in Th2 recipients. Overall survival
as similar in non-Th2 and Th2 cohorts, with a me-
ian follow-up in non-Th2 recipients of 70 months
range, 66-82 months) and a median follow-up in
h2 recipients of 49 months (range, 41-63 months);
t 36 months after transplantation, survival proba-
ilities were 53% for non-Th2 recipients and 43%
or Th2 recipients (P2  .32). Non-Th2 cohort
eaths were associated with disease relapse in 8 of 9
ases (89%), whereas Th2 cohort deaths were associ-
ted with disease relapse in 9 of 18 cases (50%).
nterpretation of these data should take into consid-
ration the nonrandomized nature of the compari-
ons, different periods of follow-up due to sequential
ccrual to the study cohorts, and heterogeneity in
atient characteristics.
ost-HSCT Lymphocyte Recovery
There was a dose-dependent, transient increase in
bsolute lymphocyte counts (ALCs) in Th2 recipients
Figure 3). Baseline ALC at day 0 before donor cell
nfusion did not differ between non-Th2 recipients
mean  SEM, 19  5 cells/L) and level 3 Th2
ecipients (42  21 cells/L; P  .33). At day 5 after
CT, ALCs were 54  9 cells/L in non-Th2 recip-
ents and 230  55 cells/L in level 3 Th2 recipients
P  .002). At day 7 after HCT, ALCs were 175  69
ells/L in non-Th2 recipients and 355 78 cells/L
n level 3 Th2 recipients (P  .019). By day 14 after
Non-Th2 Cohort (n  19) Th2 Cohort (n  28)
7.5 (4.6-12.8) 9.2 (3.5-17.8)
4.0 (1.5-8.3) 3.2 (1.7-9.4)
4.0 (1.5-8.3) 4.1 (1.9-9.4)
9 (7-11) 9 (7-13)
11 (6-24) 10 (8-12)
ge)
98% (65-100) 100% (85-100)
98% (70-100) 97% (80-100)
98% (70-100) 99% (80-100)
plantation.
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D. H. Fowler et al.1156h2 recipients were similar at 1245 142 and 1200
84 cells/L, respectively (P  .56). Recipients of
h2-like cells at dose levels 1 and 2 had modestly
ncreased ALCs, but these values were not statistically
ifferent (not shown).
ost-HSCT TCR Evaluation
Because murine Th2 cells abrogate GVL effects
33], we evaluated whether Th2 recipients developed
umor-speciﬁc T cell responses. A representative ex-
mple of the tetramer-based ﬂow cytometric assay is
hown in Figure 4A. Normal donor CD8 T cells did
ot express TCR speciﬁc for any of the differentiation
ntigens evaluated; in contrast, post-transplantation T
ells from some Th2 and non-Th2 recipients had
ncreased expression of TCR speciﬁc for SURVIVIN
Figure 4B), PRAME (Figure 4C), and WT1 (Figure
D). Negative control tetramer results (TAX) and
ositive control tetramer results (cytomegalovirus, in-
uenza matrix protein) are also shown (Figure 4E).
hese results demonstrate that allogeneic transplanta-
ion induced tumor-speciﬁc responses in Th2 and non-
h2 cohorts, thereby indicating that Th2 cells did not
brogate this potential GVL mechanism.
nflammatory Cytokines after HSCT
Relative to non-Th2 recipients, Th2 cell recipi-
nts tended to have increased monocyte TNF- pro-
uction at 2 weeks after HCT (%CD14TNF;
ean SEM, 2.2 1.0 versus 0.6 0.1; P .10) and
ad statistically signiﬁcant increases at 4 weeks (5.5 
.7 versus 0.5  0.1; P  .0001) and 6 weeks (8.3 
.2 versus 3.6 1.3; P .028) after HCT (Figure 5B).
h2 cell recipients tended to have increased monocyte
L-1 production at 2 weeks (%CD14IL-1; mean 
EM, 24.3  5.8 versus 8.7  3.7; P  .13), 4 weeks
igure 3. Absolute lymphocyte counts (ALC) after HSCT. ALC in
rotocol controls not receiving Th2 cells (n  19; —) or recipients
f dose level 3 Th2 cells (125  106 cells/kg; n  6; HD Th2) were
easured on days 0, 5, 7, and 14 after HCT (mean  SEM of
ymphocytes/L; **P  .05).55.3  5.8 versus 45.5  7.3; P  .38), and 6 weeks G46.0  4.9 versus 31.4  7.0; P  .10) after HCT
Figure 5A).
h2 Recipients Secrete Th1- and Th2-type
ytokines after HCT
A high frequency of post-HCT CD4 T cells
rom Th2 cell recipients secreted IL-2 and IFN-
Figure 6A). A high frequency of CD4 cells, identi-
ed in other stains as CD8 T cells, also secreted
FN-. Post-HCT CD4 T cells from Th2 cell re-
ipients secreted IL-4 and IL-10, but at a lower fre-
uency compared with Th1 cytokines. These results
ere consistently observed (Figure 6B), because post-
CT CD4 T cells from Th2 cell recipients secreted
L-2 (%CD4IL-2, mean  SEM, 33.3  6.8),
FN- (49.9  8.0), IL-4 (29.5  7.6), and IL-10
26.1  6.2).
ISCUSSION
In this phase I clinical trial, allograft augmentation
ith ex vivo costimulated and cytokine-polarized
D4 T cells at 5-125  106 cells/kg was relatively
afe and modulated monocyte inﬂammatory cytokine
roduction after HCT. These results represent the
nitial clinical translation of murine studies involving
ype II cytokine-polarized T cells for allograft engi-
eering.
At the high dose of Th2 cells, accelerated donor
ymphocyte engraftment occurred during cyclospor-
ne therapy. This early lymphocyte increase was com-
rised of CD4 and CD8 T cells, thereby indicating
hat the Th2 cells likely activated T cells present in
he mobilized allograft. Lymphocyte expansion in
h2 recipients was transient and not statistically sig-
iﬁcant at lower Th2 cell doses. These ﬁndings are
herefore distinct from previous data, because co-
timulated autologous T cell therapy yielded pro-
onged lymphocytosis when administered without im-
une suppression [13,14].
Allograft augmentation modulated cytokines after
ransplantation because Th2 cell recipients had in-
reased TNF- and a trend toward increased IL-1.
his cytokine activation pattern was not predicted
ecause murine Th2 cells decrease GVHD-related
nﬂammatory cytokines [7,8]. In the context of this
ytokine activation, rates of grade II-IV acute GVHD
n non-Th2 and Th2 cohorts were 63% and 64%,
espectively; these rates are similar to that observed in
atients with refractory malignancy receiving myeloa-
lative conditioning and cyclosporine prophylaxis
34]. These ﬁndings support our initial results using
onocyte IL-1 and TNF- to monitor alloreactivity
fter HCT [24] and suggest that future trials might
se this assay as a marker for potential efﬁcacy of
VHD prophylaxis. In support of this, we have re-
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Th2 Cell Allograft Augmentation 1157ently observed that addition of methotrexate or
irolimus as a second agent to the study regimen is
ssociated with fewer monocyte cytokines and de-
reased acute GVHD (unpublished data).
Unexpectedly, we found that Th2 recipients had a
igher post-transplantation frequency of T cells capa-
le of secreting IL-2 and IFN- (33.3% and 49.9%,
igure 4. Post-HCT tetramer analysis of TCR expression in T
onor/recipient pairs, day 60 or 90 post-HCT CD8 T cells were
r differentiation antigens. Subjects received cyclosporine alone (
ecipients, n  4); HLA-A2 normal donors (Normal Donors, n
ytometric data from a protocol transplant patient and a normal
ifferentiation antigen WT-1 (WT235 epitope). B, WT1 results. W
d). C, PRAME results. PRAME epitopes used were PRA100 (a),
urvivin epitope Surv1M2 was used. E, Control tetramer evaluationespectively) compared with IL-4 and IL-10 (29.5% cnd 26.1%, respectively). Interpretation of these re-
ults is somewhat limited, because the cytokine cap-
ure assay was not performed on the initial protocol
ecipients who did not receive Th2 cells. The assay
as subsequently been performed on non-Th2 sub-
ects receiving the same reduced intensity regimen on
ther NCI protocols that used cyclosporine (n 3) or
d non-Th2 recipients. In transplant cases involving HLA-A2
ed by tetramer analysis for expression of TCR speciﬁc for control
ecipients, n  4) or cyclosporine and Th2 cells (HCT  Th2
were used as concurrent control T cells. A, Representative ﬂow
for control antigens HTLV-1 (TAX) and inﬂuenza (FLU) and
itopes used were WT10 (a), WT126 (b), WT187 (c), and WT235
2 (b), PRA300 (c), and PRA 425 (d). D, SURVIVIN results. The
ed FLU, TAX, and cytomegalovirus (CMV).h2 an
evaluat
HCT R
 3)
donor
T1 ep
PRA14yclosporine/methotrexate GVHD prophylaxis (n 
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D. H. Fowler et al.11581); in these 14 subjects, the mean values for post-
ransplantation CD4 T cells capable of cytokine se-
retion in response to costimulation were relatively
ow, with values of 4.7% for IL-2, 9.0% for IFN-,
.7% for IL-4, and 1.2% for IL-10. Given this infor-
ation, we speculate that Th2 cell infusion may have
romoted Th1 and Th2 cytokine production. Because
FN- induces proinﬂammatory cytokines [35], in-
reased IFN- secretion in Th2 recipients may have
ctivated downstream monocyte IL-1 and TNF-.
f note, high post-HCT frequencies of IL-4-secret-
ng T cells and low frequencies of IFN--secreting T
ells have been associated with decreased acute
VHD [36]. The inability to attain a highly polarized
h2 state after HCT in our study may relate to (1)
h2 cell insufﬁciency (incomplete polarization, lim-
ted in vivo expansion), (2) Th2 cell inhibition by
yclosporine, and (3) presence of ﬁxed Th1 effector T
ells within the mobilized allograft. Based on these
otential factors, future clinical trials will evaluate
1) Th2 cells of enhanced function generated ex vivo
n rapamycin [37], (2) GVHD prophylaxis with rapa-
ycin, which preferentially inhibits Th1 responses
38], and (3) Th2 cell therapy using partially T cell-
igure 5. Post-transplantation monocyte cytokine secretion in T
erformed at weeks 2, 4, and 6 after HCT, with analysis of 2000 t
onocytes positive for IL-1 production (A) or TNF- production
ata for Th2 recipients pooled from each Th2 cell dose level (n
valuable; open circles).epleted allografts. sIt is important to note that clinical antitumor
esults from this study are difﬁcult to evaluate because
f the heterogenous nature of the patient population
valuated. However, because murine Th2 cells inhibit
VL effects [33], 3 observations from this study are
orth noting. First, most Th2 and non-Th2 subjects
chieved CR after HCT. Second, post-HCT deaths in
on-Th2 recipients were primarily attributed to pro-
ressive disease, whereas Th2 recipient deaths were
ore commonly attributed to nonrelapse mortality.
hird, CD8 T cells from Th2 and non-Th2 recip-
ents expressed TCR speciﬁc for antigens overex-
ressed on hematologic malignancy. Together these
ata indicate that Th2 cell therapy did not abrogate
otential immune-mediated GVL effects.
In conclusion, allogeneic CD4 T cells costimu-
ated in the presence of IL-4 and IL-2 are feasible to
enerate and relatively safe to infuse. Infusion of Th2
ells early after HSCT did not impair alloengraft-
ent or negatively inﬂuence hematopoietic recov-
ry, resulted in a balance of Th2 and Th1 cytokines,
nd activated monocyte cytokines. The Th2 cohort
eceived highly activated donor CD4 T cells but
id not have increased GVHD. Altogether, this
non-Th2 recipients. Monocyte intracellular ﬂow cytometry was
0 events per time point. Results are expressed as percent CD14
lative to isotype control samples. Data represent individual patient
ubjects evaluable; solid squares) and non-Th2 recipients (n  16h2 and
o 10 00
(B) re
 22 study provides data to guide further development
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